EUVIMEDEUVIMED entdecken
Open Access

Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis

Graeme Jones, Changhai Ding

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · 2010-01 · 3 · CMAMD.S4864

DOI: 10.4137/cmamd.s4864 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, online erschienen am 19.12.2010. Verfasst von Graeme Jones und 1 weiteren Autor:innen. Beteiligte Einrichtung: Menzies Research Institute, University of Tasmania, Hobart, Tasmania 7000, Australia. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent years have seen many exciting developments in the treatment of rheumatoid arthritis. Tocilizumab (TCZ) is a monoclonal antibody which inhibits the interleukin-6 receptor. After initial studies in Japan, it has been extensively studied in five multicentre clinical trials. This report summarises the key efficacy and toxicity findings from the major clinical trials. TCZ works quickly and effectively in rheumatoid arthritis either as monotherapy or in combination with other agents in early disease, DMARD inadequate responders, seronegative disease and after anti-TNF failure. The toxicity profile is manageable but includes infections (most notably skin and soft tissue), increases in serum cholesterol, transient decreases in neutrophil count and abnormal liver function tests (especially in combination with methotrexate). In summary, there is sufficient evidence to make TCZ a first line biologic therapy for rheumatoid arthritis especially for those who are unable to take methotrexate or who fail anti-TNF therapy.

Schlagwörter

Stichwörter der Autor:innen

clinical trialsinterleukin-6rheumatoidtherapy

Autor:innen und Institutionen

  • Menzies Research Institute, University of Tasmania, Hobart, Tasmania 7000, Australia.

Zitieren

APA

Jones, G., & Ding, C. (2010). Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 3, CMAMD.S4864. https://doi.org/10.4137/cmamd.s4864

Vancouver

Jones G, Ding C. Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2010;3:CMAMD.S4864. doi:10.4137/cmamd.s4864

BibTeX
@article{Jones2010,
  author = {Jones, Graeme and Ding, Changhai},
  title = {Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid Arthritis},
  journal = {Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders},
  year = {2010},
  volume = {3},
  pages = {CMAMD.S4864},
  doi = {10.4137/cmamd.s4864}
}
Kostenlos starten →